Discovery of a Potent and Orally Active Dual GPBAR1/CysLT(1)R Modulator for the Treatment of Metabolic Fatty Liver Disease

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are two highly prevalent human diseases caused by excessive fat deposition in the liver. Although multiple approaches have been suggested, NAFLD/NASH remains an unmet clinical need. Here, we report the discovery of a no...

Descripción completa

Detalles Bibliográficos
Autores principales: Fiorucci, Stefano, Rapacciuolo, Pasquale, Fiorillo, Bianca, Roselli, Rosalinda, Marchianò, Silvia, Di Giorgio, Cristina, Bordoni, Martina, Bellini, Rachele, Cassiano, Chiara, Conflitti, Paolo, Catalanotti, Bruno, Limongelli, Vittorio, Sepe, Valentina, Biagioli, Michele, Zampella, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085577/
https://www.ncbi.nlm.nih.gov/pubmed/35559268
http://dx.doi.org/10.3389/fphar.2022.858137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9085577/
https://www.ncbi.nlm.nih.gov/pubmed/35559268
http://dx.doi.org/10.3389/fphar.2022.858137

Ejemplares similares